July 26, 2024Open Access

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD

Key Points

Key points are not available for this paper at this time.

Abstract

Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Sun et al. (Fri,) studied this question.

synapsesocial.com/papers/68e5ee7cb6db643587582da0 https://doi.org/https://doi.org/10.3350/cmh.2024.0268

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis2017 · 1,309 citations
2Polyenephosphatidylcholine prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stress2009 · 89 citations
3A multisociety Delphi consensus statement on new fatty liver disease nomenclature2023 · 802 citations
4Isolation of Kupffer Cells and Hepatocytes from a Single Mouse Liver2017 · 104 citations
5Electron transfer-based antioxidant nanozymes: Emerging therapeutics for inflammatory diseases2023 · 41 citations

Demander à l'IA

Bookmark

View Full Paper